Organon & Co. Reports First Quarter 2026 Results

Organon & Co. reported first quarter 2026 revenue of $1.460 billion, a 4% decrease year-over-year on an as-reported basis and a 9% decrease excluding foreign currency impacts. The company reported a net income of $146 million, or $0.55 per diluted share, compared to $87 million, or $0.33 per diluted share, in the first quarter of 2025. Non-GAAP Adjusted diluted EPS was $0.71, down from $1.02 in the prior year period. The company announced its pending merger with Sun Pharmaceutical Industries Limited, an all-cash transaction expected to close in early 2027. Due to the pending merger, Organon will not provide financial guidance or host quarterly earnings calls. Key product performance highlights include a decline in Women's Health revenue, primarily due to decreased sales of Nexplanon and oral contraceptives, while Biosimilars revenue increased significantly, driven by Hadlima and new product contributions. Established Brands revenue saw a slight decline. The company declared a quarterly dividend of $0.02 per share, payable on June 11, 2026.